Leahey W J, Neill J D, Varma M P, Shanks R G
Br J Clin Pharmacol. 1980 Jan;9(1):33-40. doi: 10.1111/j.1365-2125.1980.tb04793.x.
Plasma levels of propranolol were measured at intervals after the oral administration of 160 mg propranolol and 160 mg L.A. propranolol in ten subjects who received both drugs on separate occasions. Mean peak plasma concentration of propranolol occurred 2 h after propranolol and 10 h after the L.A. formulation; the peak concentration with the former was four times that with the latter. At 24 h the plasma level was significantly higher after L.A. propranolol. Observations were made in nine healthy volunteers who exercised before and at intervals after the oral administration of 160 mg propranolol and 160 mg L.A. propranolol. Propranolol produced a maximum reduction (27.84 ± 2.4%) in the exercise tachycardia at 3 h and L.A. propranolol a maximum reduction (22.00 ± 1.73%) at 6 h. The effects at 24 h were 9.24 ± 1.55 and 16.79 ± 2.16% respectively. Five subjects were given 160 mg propranolol as a single dose daily for 8 days and on a separate occasion similar treatment with L.A. propranolol. Subjects were exercised and blood samples were taken before and 3 h after each dose on days 1 to 5 and on day 8. The reduction in the exercise tachycardia 3 h after propranolol ranged from 33.0 to 36.9% and 24 h after propranolol from 12.2 to 20.8%. The corresponding values after L.A. propranolol were 26.8 and 31.4 (3 h values) and 20.4 and 25.0 (trough values). The trough plasma levels of propranolol during administration of propranolol ranged from 10.2 to 19.4 ng/ml and peak values from 202.2 to 245.0 ng/ml. The corresponding values after L.A. propranolol were 12.5 to 17.5 (trough values) and 18.4 to 50.0 (peak values) ng/ml. These observations show that the new long acting formulation of propranolol produces a significant reduction of an exercise tachycardia throughout a 24 h period without a very high initial effect during single and multiple dosing. This formulation should be suitable for once a day administration.
在10名受试者分别服用两种药物的情况下,口服160毫克普萘洛尔和160毫克长效普萘洛尔后,定期测量血浆普萘洛尔水平。普萘洛尔的平均血浆峰值浓度在服用普萘洛尔后2小时出现,而在服用长效制剂后10小时出现;前者的峰值浓度是后者的四倍。在24小时时,长效普萘洛尔后的血浆水平显著更高。对9名健康志愿者进行了观察,他们在口服160毫克普萘洛尔和160毫克长效普萘洛尔之前及之后定期进行运动。普萘洛尔在3小时时使运动性心动过速最大降低(27.84±2.4%),长效普萘洛尔在6小时时使运动性心动过速最大降低(22.00±1.73%)。在24小时时的效果分别为9.24±1.55%和16.79±2.16%。5名受试者每天单次服用160毫克普萘洛尔,共8天,在另一个时间给予类似的长效普萘洛尔治疗。在第1至5天和第8天,每次给药前和给药后3小时让受试者运动并采集血样。普萘洛尔给药后3小时运动性心动过速的降低幅度为33.0%至36.9%,给药后24小时为12.2%至20.8%。长效普萘洛尔后的相应值为26.8和31.4(3小时的值)以及20.4和25.0(谷值)。服用普萘洛尔期间普萘洛尔的血浆谷值水平为10.2至19.4纳克/毫升,峰值为202.2至245.0纳克/毫升。长效普萘洛尔后的相应值为12.5至17.5(谷值)和18.4至50.0(峰值)纳克/毫升。这些观察结果表明,新的长效普萘洛尔制剂在24小时内可显著降低运动性心动过速,在单次和多次给药期间不会产生非常高的初始效应。这种制剂适合每日一次给药。